pre-IPO PHARMA

COMPANY OVERVIEW

Founded in December 2016, Laekna Therapeutics is an emerging innovative pharma company based in China's "Zhangjiang Pharma Valley" and New Jersey in the US, focusing on developing new ground-breaking innovative therapies to treat cancer and liver diseases. Laekna Therapeutics has adopted a two-pronged strategy in new drug development. On one hand, it continues to enrich its portfolio by introducing global new drugs with the clinical Proof of Concept. The company has obtained the global exclusive rights of four new drug candidates from Novartis. On the other hand, the company's self-developed innovative drugs will soon enter clinical development stage.


LOCATION

  • Shanghai, , China
  • Warren, NJ, USA

  • THERAPEUTIC AREAS

  • Liver Disease
  • Oncology

  • WEBSITE

    http://www.laeknatp.com


    CAREER WEBSITE

    None


    SOCIAL MEDIA


    INVESTORS



    PRESS RELEASES


    May 26, 2022

    Laekna Therapeutics Announces Dosing of First Patients in the U.S. and China in Phase Ib/III Study of Afuresertib in Combination with Fulvestrant in HR+/HER2- Breast Cancer


    May 18, 2022

    Laekna Therapeutics Raises $61 Million in Series D financing


    Mar 29, 2022

    Laekna Therapeutics Appoints Jeff Porter, Ph.D. as Chairman of Scientific Advisory Board


    Jan 9, 2022

    Laekna Therapeutics and Innovent Biologics obtain IND approval for combination therapy in patients with specific types of solid tumors who have been refractory to treatment with PD-1/PD-L1 inhibitors


    Sep 16, 2021

    Laekna Therapeutics reported positive results in two clinical studies for the treatment of various stages of prostate cancer at the ESMO Congress


    For More Press Releases


    Google Analytics Alternative